首页|NICE and easy? Ensuring equitable access to NICE-approved treatments in children and young people
NICE and easy? Ensuring equitable access to NICE-approved treatments in children and young people
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Bmj Publishing Group
The National Institute for Health and Care Excellence (NICE) recently approved Palforzia, an oral immunotherapy product for the treatment of peanut allergy in peanut-allergic children aged 4-17 years.~1 Palforzia contains precise amounts of defatted peanut powder and can be used to gradually increase the body’s ability to tolerate small amounts of peanut. It may also help reduce the severity of allergic reactions after being exposed to peanut.The approval of Palforzia represents a major step forward for the management of food-allergic patients in the National Health Service (NHS). There are approximately 140000 eligible patients with peanut allergy, but only a handful of specialist services able to provide the multiple visits needed to administer the treatment. These visits require significant space and staff resources, which many services lack. As a result, NHS England (NHSE) is limiting the number of eligible patients to 600 in the first year (and up to 2000 per annum thereafter).~2
Paul J Turner、Nick Makwana、Graham Roberts、Adam T Fox
展开 >
National Heart & Lung Institute, Imperial College London, London, UK
NSTL
Bmj Publishing Group
